| Characteristic . | Cohort 1, n (%) . | Cohort 2, n (%) . |
|---|---|---|
| Total number | 199 (100) | 215 (100) |
| Female | 182 (91.5) | 175 (81.4) |
| Agea (mean years) | 57.3 (12.0) | 57.4 (13.4) |
| Disease duration (mean years) | 12.7 (8.6) | 13.4 (9.9) |
| Scleroderma subtype | ||
| Limited | 138 (69.4) | 141 (65.6) |
| Diffuse | 61 (30.7) | 74 (34.4) |
| Overlap | 70 (35.2) | 52 (24.2) |
| Antibody category | ||
| ACA | 55 (28.1) | 68 (31.6) |
| ATA | 42 (21.4) | 55 (25.6) |
| ARA | 11 (5.6) | 26 (12.1) |
| ANA+ ENA– | 31 (15.8) | 20 (9.3) |
| Anti-U3RNP antibody | 3 (1.5) | 11 (5.1) |
| ANA negative | 6 (3.0) | 9 (4.2) |
| Anti-PM/Scl antibody | 18 (9.2) | 9 (4.2) |
| Other antibodyb | 36 (18.1) | 25 (11.6) |
| Calcinosis | ||
| Current | N/A | 69 (32.1) |
| Past | N/A | 14 (6.5) |
| At any time | 50 (25.1) | 83 (38.6) |
| Never | 149 (74.9) | 132 (61.4) |
| CC body sites, n (%) out of all with CC | ||
| 1/2–3/ id="322">3 | N/A | 17 (24.6)/28 (40.6)/24 (34.8) |
| CC size, n (%) out of all with CC | ||
| <1 id="329" cm/1–3 cm/>3 cm | N/A | 34 (49.3)/20 (29.0)/15 (21.7) |
| CC location body site(s), n (%) out of all with CC | ||
| Finger | N/A | 38 (55.1) |
| Elbow | N/A | 22 (31.9) |
| Knee | N/A | 11 (15.9) |
| Hand/wrist/forearm/shoulder | N/A | 6 (8.7)/5 (7.3)/7 (10.1)/7 (10.1) |
| Foot/leg/buttock | N/A | 4 (5.8)/3 (4.4)/2 (2.9) |
| Gastroesophageal reflux disease (GORD)c | N/A | 180 (83.7) |
| PPI use | ||
| Current | N/A | 174 (80.9) |
| Past | N/A | 8 (3.72) |
| Never | N/A | 33 (15.4) |
| Mean years on PPI | N/A | 14.5 (16.3) |
| Characteristic . | Cohort 1, n (%) . | Cohort 2, n (%) . |
|---|---|---|
| Total number | 199 (100) | 215 (100) |
| Female | 182 (91.5) | 175 (81.4) |
| Agea (mean years) | 57.3 (12.0) | 57.4 (13.4) |
| Disease duration (mean years) | 12.7 (8.6) | 13.4 (9.9) |
| Scleroderma subtype | ||
| Limited | 138 (69.4) | 141 (65.6) |
| Diffuse | 61 (30.7) | 74 (34.4) |
| Overlap | 70 (35.2) | 52 (24.2) |
| Antibody category | ||
| ACA | 55 (28.1) | 68 (31.6) |
| ATA | 42 (21.4) | 55 (25.6) |
| ARA | 11 (5.6) | 26 (12.1) |
| ANA+ ENA– | 31 (15.8) | 20 (9.3) |
| Anti-U3RNP antibody | 3 (1.5) | 11 (5.1) |
| ANA negative | 6 (3.0) | 9 (4.2) |
| Anti-PM/Scl antibody | 18 (9.2) | 9 (4.2) |
| Other antibodyb | 36 (18.1) | 25 (11.6) |
| Calcinosis | ||
| Current | N/A | 69 (32.1) |
| Past | N/A | 14 (6.5) |
| At any time | 50 (25.1) | 83 (38.6) |
| Never | 149 (74.9) | 132 (61.4) |
| CC body sites, n (%) out of all with CC | ||
| 1/2–3/ id="322">3 | N/A | 17 (24.6)/28 (40.6)/24 (34.8) |
| CC size, n (%) out of all with CC | ||
| <1 id="329" cm/1–3 cm/>3 cm | N/A | 34 (49.3)/20 (29.0)/15 (21.7) |
| CC location body site(s), n (%) out of all with CC | ||
| Finger | N/A | 38 (55.1) |
| Elbow | N/A | 22 (31.9) |
| Knee | N/A | 11 (15.9) |
| Hand/wrist/forearm/shoulder | N/A | 6 (8.7)/5 (7.3)/7 (10.1)/7 (10.1) |
| Foot/leg/buttock | N/A | 4 (5.8)/3 (4.4)/2 (2.9) |
| Gastroesophageal reflux disease (GORD)c | N/A | 180 (83.7) |
| PPI use | ||
| Current | N/A | 174 (80.9) |
| Past | N/A | 8 (3.72) |
| Never | N/A | 33 (15.4) |
| Mean years on PPI | N/A | 14.5 (16.3) |
Cohort 1: age at first DEXA scan; cohort 2: age at study enrolment.
Other antibodies include nRNP, Ro, La, Th/To, SL, hnRNP, NOR90, Mi2, Ku. GORD defined as a history of reflux symptoms or a diagnosis of gastroesophageal reflux documented in patient notes.
ATA: anti-topoisomerase I antibody; ARA: anti-RNA polymerase III antibody; CC: current calcinosis; N/A: not available; GORD: gastroesophageal reflux disease; PPI: proton pump inhibitor.
| Characteristic . | Cohort 1, n (%) . | Cohort 2, n (%) . |
|---|---|---|
| Total number | 199 (100) | 215 (100) |
| Female | 182 (91.5) | 175 (81.4) |
| Agea (mean years) | 57.3 (12.0) | 57.4 (13.4) |
| Disease duration (mean years) | 12.7 (8.6) | 13.4 (9.9) |
| Scleroderma subtype | ||
| Limited | 138 (69.4) | 141 (65.6) |
| Diffuse | 61 (30.7) | 74 (34.4) |
| Overlap | 70 (35.2) | 52 (24.2) |
| Antibody category | ||
| ACA | 55 (28.1) | 68 (31.6) |
| ATA | 42 (21.4) | 55 (25.6) |
| ARA | 11 (5.6) | 26 (12.1) |
| ANA+ ENA– | 31 (15.8) | 20 (9.3) |
| Anti-U3RNP antibody | 3 (1.5) | 11 (5.1) |
| ANA negative | 6 (3.0) | 9 (4.2) |
| Anti-PM/Scl antibody | 18 (9.2) | 9 (4.2) |
| Other antibodyb | 36 (18.1) | 25 (11.6) |
| Calcinosis | ||
| Current | N/A | 69 (32.1) |
| Past | N/A | 14 (6.5) |
| At any time | 50 (25.1) | 83 (38.6) |
| Never | 149 (74.9) | 132 (61.4) |
| CC body sites, n (%) out of all with CC | ||
| 1/2–3/ id="322">3 | N/A | 17 (24.6)/28 (40.6)/24 (34.8) |
| CC size, n (%) out of all with CC | ||
| <1 id="329" cm/1–3 cm/>3 cm | N/A | 34 (49.3)/20 (29.0)/15 (21.7) |
| CC location body site(s), n (%) out of all with CC | ||
| Finger | N/A | 38 (55.1) |
| Elbow | N/A | 22 (31.9) |
| Knee | N/A | 11 (15.9) |
| Hand/wrist/forearm/shoulder | N/A | 6 (8.7)/5 (7.3)/7 (10.1)/7 (10.1) |
| Foot/leg/buttock | N/A | 4 (5.8)/3 (4.4)/2 (2.9) |
| Gastroesophageal reflux disease (GORD)c | N/A | 180 (83.7) |
| PPI use | ||
| Current | N/A | 174 (80.9) |
| Past | N/A | 8 (3.72) |
| Never | N/A | 33 (15.4) |
| Mean years on PPI | N/A | 14.5 (16.3) |
| Characteristic . | Cohort 1, n (%) . | Cohort 2, n (%) . |
|---|---|---|
| Total number | 199 (100) | 215 (100) |
| Female | 182 (91.5) | 175 (81.4) |
| Agea (mean years) | 57.3 (12.0) | 57.4 (13.4) |
| Disease duration (mean years) | 12.7 (8.6) | 13.4 (9.9) |
| Scleroderma subtype | ||
| Limited | 138 (69.4) | 141 (65.6) |
| Diffuse | 61 (30.7) | 74 (34.4) |
| Overlap | 70 (35.2) | 52 (24.2) |
| Antibody category | ||
| ACA | 55 (28.1) | 68 (31.6) |
| ATA | 42 (21.4) | 55 (25.6) |
| ARA | 11 (5.6) | 26 (12.1) |
| ANA+ ENA– | 31 (15.8) | 20 (9.3) |
| Anti-U3RNP antibody | 3 (1.5) | 11 (5.1) |
| ANA negative | 6 (3.0) | 9 (4.2) |
| Anti-PM/Scl antibody | 18 (9.2) | 9 (4.2) |
| Other antibodyb | 36 (18.1) | 25 (11.6) |
| Calcinosis | ||
| Current | N/A | 69 (32.1) |
| Past | N/A | 14 (6.5) |
| At any time | 50 (25.1) | 83 (38.6) |
| Never | 149 (74.9) | 132 (61.4) |
| CC body sites, n (%) out of all with CC | ||
| 1/2–3/ id="322">3 | N/A | 17 (24.6)/28 (40.6)/24 (34.8) |
| CC size, n (%) out of all with CC | ||
| <1 id="329" cm/1–3 cm/>3 cm | N/A | 34 (49.3)/20 (29.0)/15 (21.7) |
| CC location body site(s), n (%) out of all with CC | ||
| Finger | N/A | 38 (55.1) |
| Elbow | N/A | 22 (31.9) |
| Knee | N/A | 11 (15.9) |
| Hand/wrist/forearm/shoulder | N/A | 6 (8.7)/5 (7.3)/7 (10.1)/7 (10.1) |
| Foot/leg/buttock | N/A | 4 (5.8)/3 (4.4)/2 (2.9) |
| Gastroesophageal reflux disease (GORD)c | N/A | 180 (83.7) |
| PPI use | ||
| Current | N/A | 174 (80.9) |
| Past | N/A | 8 (3.72) |
| Never | N/A | 33 (15.4) |
| Mean years on PPI | N/A | 14.5 (16.3) |
Cohort 1: age at first DEXA scan; cohort 2: age at study enrolment.
Other antibodies include nRNP, Ro, La, Th/To, SL, hnRNP, NOR90, Mi2, Ku. GORD defined as a history of reflux symptoms or a diagnosis of gastroesophageal reflux documented in patient notes.
ATA: anti-topoisomerase I antibody; ARA: anti-RNA polymerase III antibody; CC: current calcinosis; N/A: not available; GORD: gastroesophageal reflux disease; PPI: proton pump inhibitor.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
